These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up. Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496 [TBL] [Abstract][Full Text] [Related]
64. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies]. González-Gay MA; Agudo M Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386 [No Abstract] [Full Text] [Related]
65. Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Joseph GJ; Harrison DJ; Sauer BC Adv Ther; 2016 Aug; 33(8):1347-59. PubMed ID: 27352377 [TBL] [Abstract][Full Text] [Related]
66. Appearance of rheumatoid nodules following anti-tumor necrosis factor alpha treatment with adalimumab for rheumatoid arthritis. Scrivo R; Spadaro A; Iagnocco A; Valesini G Clin Exp Rheumatol; 2007; 25(1):117. PubMed ID: 17418005 [No Abstract] [Full Text] [Related]
67. [New drugs and treatment strategies for rheumatoid arthritis]. Fantini F Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798 [TBL] [Abstract][Full Text] [Related]
68. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. Taylor PC; Keystone EC; van der Heijde D; Weinblatt ME; Del Carmen Morales L; Reyes Gonzaga J; Yakushin S; Ishii T; Emoto K; Beattie S; Arora V; Gaich C; Rooney T; Schlichting D; Macias WL; de Bono S; Tanaka Y N Engl J Med; 2017 Feb; 376(7):652-662. PubMed ID: 28199814 [TBL] [Abstract][Full Text] [Related]
69. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748 [TBL] [Abstract][Full Text] [Related]
70. Power Doppler ultrasound monitoring of response to anti-tumour necrosis factor alpha treatment in patients with rheumatoid arthritis. Iagnocco A; Finucci A; Ceccarelli F; Perricone C; Iorgoveanu V; Valesini G Rheumatology (Oxford); 2015 Oct; 54(10):1890-6. PubMed ID: 26070937 [TBL] [Abstract][Full Text] [Related]
71. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133 [TBL] [Abstract][Full Text] [Related]
72. Adalimumab therapy in rheumatoid arthritis. Keystone E; Haraoui B Rheum Dis Clin North Am; 2004 May; 30(2):349-64, vii. PubMed ID: 15172045 [TBL] [Abstract][Full Text] [Related]
73. Scabies in a Patient with Rheumatoid Arthritis Treated with Adalimumab - A Case Report. Marković I; Pukšić S; Gudelj Gračanin A; Čulo MI; Mitrović J; Morović-Vergles J Acta Dermatovenerol Croat; 2015; 23(3):195-8. PubMed ID: 26476903 [TBL] [Abstract][Full Text] [Related]
74. Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels. Romano E; Terenzi R; Manetti M; Peruzzi F; Fiori G; Nacci F; Bellando-Randone S; Matucci-Cerinic M; Guiducci S J Rheumatol; 2014 Oct; 41(10):1961-5. PubMed ID: 25179850 [TBL] [Abstract][Full Text] [Related]
76. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany. Li N; Betts KA; Messali AJ; Skup M; Garg V Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087 [TBL] [Abstract][Full Text] [Related]
78. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. van Herwaarden N; van der Maas A; Minten MJ; van den Hoogen FH; Kievit W; van Vollenhoven RF; Bijlsma JW; van den Bemt BJ; den Broeder AA BMJ; 2015 Apr; 350():h1389. PubMed ID: 25858265 [TBL] [Abstract][Full Text] [Related]